DexComDXCM
DXCM
About: DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Employees: 10,300
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
30% more capital invested
Capital invested by funds: $24.3B [Q1] → $31.6B (+$7.25B) [Q2]
23% more first-time investments, than exits
New positions opened: 123 | Existing positions closed: 100
14% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 8 (+1) [Q2]
1.01% more ownership
Funds ownership: 91.35% [Q1] → 92.36% (+1.01%) [Q2]
0% less funds holding
Funds holding: 917 [Q1] → 916 (-1) [Q2]
3% less repeat investments, than reductions
Existing positions increased: 330 | Existing positions reduced: 339
5% less call options, than puts
Call options by funds: $415M | Put options by funds: $439M
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$89
17%
upside
Avg. target
$101
33%
upside
High target
$106
40%
upside
11 analyst ratings
9 positive
82%
2 neutral
18%
0 negative
0%
Argus Research Steve Silver | 32%upside $100 | Buy Initiated | 21 Aug 2025 |
Canaccord Genuity William Plovanic | 40%upside $106 | Buy Maintained | 1 Aug 2025 |
Raymond James Jayson Bedford | 34%upside $102 | Strong Buy Maintained | 31 Jul 2025 |
Piper Sandler Matt O'Brien | 32%upside $100 | Overweight Maintained | 31 Jul 2025 |
UBS Danielle Antalffy | 40%upside $106 | Buy Maintained | 31 Jul 2025 |
Financial journalist opinion
Based on 16 articles about DXCM published over the past 30 days
Neutral
Zacks Investment Research
5 days ago
DexCom Expands Access and Innovation While Balancing Headwinds
DXCM grows on type 2 access, Stelo adoption, and new sensor launches, but faces margin pressures, competition and leadership transition.
Neutral
The Motley Fool
1 week ago
2 Stocks to Buy on the Dip and Hold for 10 Years
Despite President Donald Trump's trade wars and concerns about a possible recession, equity markets have performed relatively well this year, with the S&P 500 (^GSPC -0.29%) up 10% since January. Some corporations, however, have not been as fortunate, including PayPal (PYPL -0.20%) and DexCom (DXCM 1.23%), both of which have underperformed the market due to company-specific issues.
Neutral
GlobeNewsWire
2 weeks ago
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DexCom, Inc. (NASDAQ: DXCM) on behalf of long-term stockholders following a class action complaint that was filed against DexCom on August 21, 2024 with a Class Period from January 8, 2024 to July 25, 2024. Our investigation concerns whether the board of directors of DexCom have breached their fiduciary duties to the company.
Positive
CNBC Television
2 weeks ago
Dexcom's Arizona facility can service good portion of U.S. business, says CEO
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.
Positive
The Motley Fool
3 weeks ago
DexCom (DXCM) Q2 Revenue Jumps 15%
DexCom (DXCM) Q2 Revenue Jumps 15%
Positive
Market Watch
3 weeks ago
10 stocks favored to gain up to 30% in a sector that has missed this year's rally
All but two of the S&P 500's sectors are up so far in 2025.
Positive
Zacks Investment Research
3 weeks ago
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
Neutral
Seeking Alpha
3 weeks ago
DexCom, Inc. (DXCM) Q2 2025 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Jacob Steven Leach - President & COO Jereme M. Sylvain - Executive VP, CFO & Chief Accounting Officer Kevin Ronald Sayer - Executive Chairman & CEO Sean Christensen - Vice President of Finance and Investor Relations Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.
Positive
Zacks Investment Research
3 weeks ago
Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Positive
Zacks Investment Research
3 weeks ago
DexCom (DXCM) Q2 Earnings and Revenues Top Estimates
DexCom (DXCM) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago.
Charts implemented using Lightweight Charts™